Headlines about BioSpecifics Technologies (NASDAQ:BSTC) have trended positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioSpecifics Technologies earned a news impact score of 0.34 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.899685555857 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
BioSpecifics Technologies (NASDAQ BSTC) traded down $0.19 during trading on Wednesday, reaching $43.25. The company’s stock had a trading volume of 6,047 shares, compared to its average volume of 27,469. The company has a market capitalization of $312.16, a P/E ratio of 27.32 and a beta of 1.55. BioSpecifics Technologies has a twelve month low of $38.05 and a twelve month high of $58.79.
Several research analysts have commented on the company. dropped their price target on BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 15th. HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of BioSpecifics Technologies in a report on Tuesday. Finally, Zacks Investment Research cut BioSpecifics Technologies from a “buy” rating to a “hold” rating in a research note on Friday, January 12th.
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.